Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of PF-08634404 plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in previously untreated metastatic colorectal cancer
MOH_2026-02-16_015661Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Feb 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of PF-08634404, bevacizumab, folinic acid, fluorouracil and oxaliplatin in colorectal cancer (CRC) and colorectal adenocarcinoma (2 arms), sponsored by Pfizer. Primary endpoints: Progression-free survival and Overall survival. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
PF-08634404bevacizumabfolinic acidfluorouraciloxaliplatin
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on MOH_2026-02-16_015661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-02-16_015661.